Skip to content

US · ACTU · BIOTECHNOLOGY

Actuate Therapeutics Inc (ACTU) intrinsic value and stock valuation

$0.23as of 2026-11-21 · Mkt cap 27.04M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Actuate Therapeutics Inc DCF and intrinsic value

InvestorsCraft values ACTU with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ACTU’s statements →

Actuate Therapeutics Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Fort Worth, TX 76107 actuatetherapeutics.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-22.23M
20222025
Free cash flow
-$-19.21M
20222025
Total equity
$7.92M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Operating income-$-22.5M-$-25.16M-$-24.97M-$-20.21M
Net income-$-22.23M-$-27.29M-$-24.74M-$-20.16M
EPSd-$-1.06M-$-1.4M-$-1.65M-$-1.34M
Operating cash flow-$-19.21M-$-21.84M-$-21.63M-$-17.79M
Capital expenditure$0.00$0.00$0.00$0.00
Free cash flow-$-19.21M-$-21.84M-$-21.63M-$-17.79M
Total assets$14M$9.32M$3M$20.5M
Total debt$400K$0.00$0.00$400K
Net debt-$-12.75M-$-8.64M-$-2.96M-$-20.04M
Total equity$7.92M$100K-$-99.63M$14.8M
Cash and short-term investments$13.2M$8.64M$2.96M$20.5M
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00
Research and development expenses$10.3M$18.7M$21.7M$16.4M
Selling, general and administrative expenses$12.2M$6.48M$3.27M$3.82M
Other expenses$0.00$0.00$0.00$0.00
Operating expenses$22.5M$25.2M$25M$20.2M
Cost and expenses$22.5M$25.2M$25M$20.2M
Interest income$290K$220K$350K$30K
Interest expense$20K-$-20K$40K$20K
Depreciation and amortization$0.00$2.14M$270K$60K
Ebitda-$-22.21M-$-25.16M-$-24.43M-$-20.08M
Operating income-$-22.5M-$-25.16M-$-24.97M-$-20.21M
Total other income/expenses, net$270K-$-2.12M$230K$50K
Income before tax-$-22.23M-$-27.28M-$-24.74M-$-20.16M
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-22.23M-$-27.29M-$-24.74M-$-20.16M
Weighted average shares outstanding$21M$19.5M$15M$15M
Weighted average diluted shares outstanding$21M$19.5M$15M$15M
Balance sheet
2025202420232022
Cash and short-term investments$13.2M$8.64M$2.96M$20.5M
Net receivables$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$13.6M$9.21M$3M$20.5M
Property, plant and equipment, net$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00
Total non-current assets$390K$110K$0.00$0.00
Total assets$14M$9.32M$3M$20.5M
Accounts payable$1.52M$1.92M$3.42M$2.13M
Short-term debt$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$5.71M$8.8M$6.92M$4.34M
Long-term debt$400K$0.00$0.00$400K
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$400K$410K$95.7M$1.31M
Capital lease obligations$0.00$0.00$0.00$0.00
Total liabilities$6.11M$9.21M$102.6M$5.65M
Common stock$0.00$0.00$0.00$0.00
Retained earnings-$-154.61M-$-132.38M-$-105.09M-$-80.35M
Accumulated other comprehensive income (loss)$0.00$0.00-$0.00$0.00
Total equity$7.92M$100K-$-99.63M$14.8M
Total investments$0.00$0.00$0.00$0.00
Total debt$400K$0.00$0.00$400K
Net debt-$-12.75M-$-8.64M-$-2.96M-$-20.04M
Cash flow statement
2025202420232022
Net income-$-22.23M-$-27.29M-$-24.74M-$-20.16M
Depreciation and amortization$0.00$0.00$0.00$0.00
Stock-based compensation$6.05M$2M$420K$650K
Change in working capital-$-3.05M$1.1M$2.57M$1.73M
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable-$-510K-$-1.5M$1.29M$590K
Net cash provided by operating activities-$-19.21M-$-21.84M-$-21.63M-$-17.79M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00
Common stock issued$24M$24M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$23.7M$27.5M$4.13M$19.3M
Net change in cash$4.52M$5.68M-$-17.49M$1.46M
Cash at end of period$13.2M$8.64M$2.96M$20.5M
Operating cash flow-$-19.21M-$-21.84M-$-21.63M-$-17.79M
Capital expenditure$0.00$0.00$0.00$0.00
Free cash flow-$-19.21M-$-21.84M-$-21.63M-$-17.79M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Actuate Therapeutics Inc

        Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.

        CEO
        Daniel Schmitt
        Employees
        12
        Beta
        0.78

        Explore

        Frequently asked questions

        What is the intrinsic value of Actuate Therapeutics Inc (ACTU)?

        InvestorsCraft does not currently publish an intrinsic value for ACTU. How the IC value is calculated.

        Is ACTU undervalued?

        InvestorsCraft does not publish an undervaluation signal for ACTU at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.